2006 (14 Publikationen)
- Ziemssen F, Warga M, Neuhann IM, Leitritz M, Biester S, Grisanti S, Bartz-Schmidt KU; The Tuebingen Bevacizumab Study Group. Does intravitreal injection of bevacizumab have an effect on the blood-aqueous barrier function? Br J Ophthalmol 2006; 90: 922 [IF 2.524]
- Szurman P, Warga M, Grisanti S, Roters S, Rohrbach JM, Aisenbrey S, Kaczmarek RT, Bartz-Schmidt KU. Sutureless amniotic membrane fixation using fibrin glue for ocular surface reconstruction in a rabbit model. Cornea 2006; 25:460-466 [IF 1.708]
- Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU; Tuebingen Bevacizumab Study Group. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 2006; 142: 158-160 [IF 2.468]
- Aisenbrey S, Lafaut BA, Szurman P, Hilgers R-D, Esser P, Walter P, Bartz-Schmidt KU, Thumann G. Iris pigment epithelial translocation in the treatment of exudative macular degeneration: A three-year follow-up. Arch Ophthalmol 2006; 124:183-188 [IF 3.206]
- Rohrbach JM, Süsskind D, Szurman P, Siepmann K. Hornhautstaphylom-Vorderkammeragenesie-Mikrophakie-Syndrom. Klin Monatsbl Augenheilkd 2006; 223: 168-75 [IF 0.679]
- Jaissle GB, Ziemssen F, Petermeier K, Szurman P, Ladewig M, Gelisken F, Völker M, Holz FG, Bartz-Schmidt KU. Bevacizumab zur Therapie des sekundären Makulaödems nach venösen Gefäßverschlüssen. Ophthalmologe 2006; 103: 471-475 [IF 0.762]
- Karim-Zade K, Mielke J, Besch D, Szurman P, Ernemann U, Herzau V. Choroidales Effusionssyndrom nach Embolisation einer indirekten Sinus-cavernosus-Fistel über die V. ophthalmica superior. Ophthalmologe 2006; 103: 609-611 [IF 0.762]
- Szurman P, Kaczmarek R, Spitzer MS, Jaissle GB, Decker P, Grisanti S, Henke-Fahle S, Aisenbrey S, Bartz-Schmidt KU. Differential toxic effect of dissolved triamcinolone and its crystalline deposits on cultured human retinal pigment epithelium (ARPE19) cells. Exp Eye Res 2006; 83: 584-592 [IF 2.776]
- Spitzer MS, Wallenfels-Thilo B, Sierra A, Yoeruek E, Peters S, Henke-Fahle S, Bartz-Schmidt KU, Szurman P. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol. 2006; 90: 1316-1321 [IF 2.524]
- Szurman P, Warga M, Bartz-Schmidt KU. Correspondence: Reply to Liu DTL, Chi-Lai L, Lee VYW, Lam DSC. Experimental implantation and long-term testing of an Intraocular Vision Aid in rabbits. Arch Ophthalmol 2006; 124: 610 [IF 3.206]
- Szurman P, Roters S, Grisanti S, Aisenbrey S, Schraermeyer U, Lüke M, Bartz-Schmidt KU, Thumann G. Ultrastructural changes following artificial retinal detachment with modified retinal adhesion. Invest Ophthalmol Vis Sci 2006; 47: 4983-4989 [IF 3.766]
- Szurman P, Petermeier K, Jaissle GB, Spitzer MS, Bartz-Schmidt, KU. Injektorimplantation sklerafixierter Faltlinsen. Ophthalmologe 2006; 103: 1020-1026 [IF 0.762]
- Rohrbach JM, Szurman P, El-Wardani ME, Grüb M. Zur Häufigkeit der exzessiven Verdickung der epithelialen Basalmembran beim Keratokonus. Klin Monatsbl Augenheilkd 2006; 223: 889-893 [IF 0.679]
- Lüke M, Warga M, Ziemssen F, Gelisken F, Grisanti S, Schneider T, Lüke C, Partsch M, Bartz-Schmidt KU, Szurman P. Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol 2006; 90: 1178-1182 [IF 2.524]
